Chiara Brando
About
Chiara Brando is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Chiara Brando has authored 34 papers receiving a total of 491 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Chiara Brando's work include Cancer Immunotherapy and Biomarkers (10 papers), BRCA gene mutations in cancer (8 papers) and Genetic factors in colorectal cancer (6 papers). Chiara Brando is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), BRCA gene mutations in cancer (8 papers) and Genetic factors in colorectal cancer (6 papers). Chiara Brando collaborates with scholars based in Italy, France and Belgium. Chiara Brando's co-authors include Viviana Bazan, Daniele Fanale, Antonio Russo, Lidia Rita Corsini, Giuseppe Badalamenti, Lorena Incorvaia, Alessia Fiorino, Clarissa Filorizzo, Marco Bono and Nadia Barraco and has published in prestigious journals such as Journal of Clinical Oncology, Oncogene and Annals of Oncology.
In The Last Decade
Chiara Brando
32 papers receiving 486 citations
Peers
Chiara Brando
Federica Panebianco United States
Linda Henry United Kingdom
Monika Migdalska‐Sęk Poland
Anna Berg Norway
Αναστασία Κοττόρου Greece
Francesca Ligorio Italy
Madalena Gomes Portugal
Dejuan Yang China
Elaine Cristina Morari Brazil
Citations per year, relative to Chiara Brando Chiara Brando (= 1×)
peers
Federica Panebianco
Countries citing papers authored by Chiara Brando
Since
Specialization
Citations
This map shows the geographic impact of Chiara Brando's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chiara Brando with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chiara Brando more than expected).
Fields of papers citing papers by Chiara Brando
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Chiara Brando. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chiara Brando. The network helps show where Chiara Brando may publish in the future.
Co-authorship network of co-authors of Chiara Brando
This figure shows the co-authorship network connecting the top 25 collaborators of Chiara Brando. A scholar is included among the top collaborators of Chiara Brando based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chiara Brando. Chiara Brando is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Incorvaia, Lorena, Cláudia Marchetti, Chiara Brando, et al.. (2025). BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study. ESMO Open. 10(2). 104076–104076.
2.
Incorvaia, Lorena, Tancredi Didier Bazan Russo, Valerio Gristina, et al.. (2024). The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors. npj Precision Oncology. 8(1). 190–190.
3.
Corsini, Lidia Rita, Chiara Brando, Alessandro Perez, et al.. (2024). 208P Role of plasma exosomes in crosstalk between immune system and hereditary ovarian cancer: Opportunity or challenge?. Annals of Oncology. 35. S300–S300.
4.
Fanale, Daniele, Lidia Rita Corsini, Erika Pedone, et al.. (2023). Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one?. Critical Reviews in Oncology/Hematology. 190. 104086–104086.
5.
Incorvaia, Lorena, Chiara Brando, Alessandro Perez, et al.. (2023). Real life use of biomarkers of homologous recombination deficiency (HRD) status beyond BRCA to predict the effectiveness of PARP inhibitors in ovarian cancer patients.. Journal of Clinical Oncology. 41(16_suppl). 10592–10592.
6.
Incorvaia, Lorena, Gaetana Rinaldi, Giuseppe Badalamenti, et al.. (2023). Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay. Therapeutic Advances in Medical Oncology. 15. 2596581–2596581.
7.
Fanale, Daniele, Lidia Rita Corsini, Chiara Brando, et al.. (2022). Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?. Critical Reviews in Oncology/Hematology. 170. 103597–103597.
8.
Fanale, Daniele, Chiara Brando, Lidia Rita Corsini, et al.. (2022). MUTYH-associated tumor syndrome: The other face of MAP. Oncogene. 41(18). 2531–2539.
9.
Fanale, Daniele, Erika Pedone, Chiara Brando, et al.. (2022). Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer. Cancers. 14(18). 4344–4344.
10.
Fanale, Daniele, Chiara Brando, Alessia Fiorino, et al.. (2021). POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes. Oncogene. 40(40). 5893–5901.
11.
Incorvaia, Lorena, Lidia Rita Corsini, Chiara Brando, et al.. (2021). Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors. Critical Reviews in Oncology/Hematology. 163. 103390–103390.
12.
Filorizzo, Clarissa, Daniele Fanale, Chiara Brando, et al.. (2021). Role of the HIPPO pathway as potential key player in the cross talk between oncology and cardiology. Critical Reviews in Oncology/Hematology. 159. 103246–103246.
13.
Fanale, Daniele, Lorena Incorvaia, Giuseppe Badalamenti, et al.. (2021). Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?. Cancers. 13(9). 2118–2118.
14.
Brando, Chiara, Daniele Fanale, Lorena Incorvaia, et al.. (2021). 32P Can circulating immune checkpoints and KIT exon 11 mutations be prognostic factors in metastatic gastrointestinal stromal tumors?. Annals of Oncology. 32. S1386–S1386.
15.
Fanale, Daniele, Alessia Fiorino, Lorena Incorvaia, et al.. (2021). Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome. Frontiers in Oncology. 11. 682445–682445.
16.
Incorvaia, Lorena, Daniele Fanale, Giuseppe Badalamenti, et al.. (2020). A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming. Cancers. 12(11). 3396–3396.
17.
Incorvaia, Lorena, Daniele Fanale, Giuseppe Badalamenti, et al.. (2020). Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. OncoImmunology. 9(1). 1832348–1832348.
18.
Fanale, Daniele, Lorena Incorvaia, Clarissa Filorizzo, et al.. (2020). Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2. Cancers. 12(9). 2415–2415.
19.
Fanale, Daniele, Lorena Incorvaia, Marco Bono, et al.. (2020). 247P Population-based testing for hereditary breast and ovarian cancer in a cohort of 1,346 patients from Southern Italy (Sicily): When historical background affects genetics. Annals of Oncology. 31. S338–S339.
20.
Nebbia, Carlo, Chiara Brando, Elisa Burdino, et al.. (1987). Effects of the chronic administration of sodium selenite on rat testes.. PubMed. 58(2). 183–97.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Federica Panebianco Breakdown of academic impact, for papers by Linda Henry Breakdown of academic impact, for papers by Monika Migdalska‐Sęk Breakdown of academic impact, for papers by Anna Berg Breakdown of academic impact, for papers by Αναστασία Κοττόρου Breakdown of academic impact, for papers by Lígia Vera Montali da Assumpção Breakdown of academic impact, for papers by Francesca Ligorio Breakdown of academic impact, for papers by Madalena Gomes Breakdown of academic impact, for papers by Dejuan Yang Breakdown of academic impact, for papers by Elaine Cristina Morari